No therapeutic strategies have been proposed to target TP53 deletion cancers until a recent report demonstrated that TP53 heterozygous deletion predisposes cancer cells to further suppression of POLR2A, a neighboring gene undergoing concomitant deletion (Bradner, 2015; Errico, 2015; Liu et al., 2015). This evidence concerns the gene TP53 and cancer.